This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Articles

(Circulation. 2005;111:3015.)
© 2005 American Heart Association, Inc.

Issue Highlights

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	ALDOSTERONE SYNTHASE INHIBITOR AMELIORATES ANGIOTENSIN II–INDUCED ORGAN DAMAGE, by Fiebeler et al.

 
Aldosterone has been shown to contribute to angiotensin II–induced end-organ damage, and clinical studies have confirmed the benefit of adding aldosterone antagonists to angiotensin-converting enzyme inhibitor agents to prevent adverse remodeling. Angiotensin II increases circulating levels of aldosterone levels as well as de novo tissue synthesis of aldosterone by stimulating aldosterone synthase (CYP11B2); however, it is unknown which source of aldosterone plays a greater role in tissue remodeling and damage. In these studies, Fiebeler et al examine this question by utilizing both FAD286, a novel CYP11B2 inhibitor, and adrenalectomy in transgenic rats overexpressing human renin and angiotensinogen genes. Using these models, they are able to isolate the source of aldosterone that modulates some of the adverse cardiac and renal effects associated with hyperaldosteronism. See p 3087.

	LONG-TERM RESPONSE TO CALCIUM CHANNEL BLOCKERS IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION, by Sitbon et al.

 
Characteristics of patients with idiopathic pulmonary arterial hypertension (IPAH) who benefit from long-term calcium channel blockers (CCBs) are unknown. Sitbon and colleagues performed acute pulmonary vasodilator testing with epoprostenol or nitric oxide during initial right heart catheterization in 557 IPAH patients. Acute responders were treated initially with oral CCB. Long-term CCB responders were defined as those being in functional class I or II after at least 1 year on CCB monotherapy. Among the 70 patients (12.6%) who displayed acute pulmonary vasoreactivity and received CCB therapy, 38 (6.7%) improved long term. Long-term CCB responders had less severe disease at baseline and displayed a more pronounced fall in mean pulmonary artery pressure during acute vasodilator testing. Of note, long-term CCB responders represented less than 10% . . . [Full Text of this Article]

Related Articles:

How to Respond to an Implantable Cardioverter-Defibrillator Shock

Samuel F. Sears, Jr, Julie B. Shea, and Jamie B. Conti
Circulation 2005 111: e380-e382. [Extract] [Full Text]

Reversible Right Ventricular Hypertrophy Due to Cardiac Sarcoidosis

Hideo Okamura, Yoichi Goto, Masahiro Terashima, Shuichi Takagi, H. Ishibashi-Ueda, and Hiroshi Nonogi
Circulation 2005 111: e383-e384. [Extract] [Full Text]

Three-Dimensional Imaging in Rupture of Papillary Muscle After Acute Myocardial Infarction

Vito Marangelli, Luisa Cacciavillani, Sara Pontarollo, Francesca di Marco, Gino Gerosa, and Sabino Iliceto
Circulation 2005 111: e385-e387. [Extract] [Full Text]

Angiosarcoma of the Pericardium: A Fatal Disease

Stijn L. Brinckman and Poll van der Wouw
Circulation 2005 111: e388-e389. [Extract] [Full Text]

Letters Regarding Article by Roguin et al, "Modern Pacemaker and Implantable Cardioverter/Defibrillator Systems Can Be Magnetic Resonance Imaging Safe: In Vitro and In Vivo Assessment of Safety and Function at 1.5 T" • Letters Regarding Article by Roguin et al, "Modern Pacemaker and Implantable Cardioverter/Defibrillator Systems Can Be Magnetic Resonance Imaging Safe: In Vitro and In Vivo Assessment of Safety and Function at 1.5 T" • Letters Regarding Article by Roguin et al, "Modern Pacemaker and Implantable Cardioverter/Defibrillator Systems Can Be Magnetic Resonance Imaging Safe: In Vitro and In Vivo Assessment of Safety and Function at 1.5 T"

Carol A. Chen-Scarabelli, Tiziano M. Scarabelli, Christian Vahlhaus, Torsten Sommer, Claas Philip Naehle, Ariel Roguin, Menekhem M. Zviman, Glenn R. Meininger, Timm M. Dickfeld, Albert Lardo, Ronald D. Berger, Hugh Calkins, Henry R. Halperin, E. Rene Rodriguez, and David A. Bluemke
Circulation 2005 111: e390-e392. [Extract] [Full Text]

Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension

Olivier Sitbon, Marc Humbert, Xavier Jaïs, Vincent Ioos, Abdul M. Hamid, Steeve Provencher, Gilles Garcia, Florence Parent, Philippe Hervé, and Gérald Simonneau
Circulation 2005 111: 3105-3111. [Abstract] [Full Text]

Apolipoprotein E Mimetic Peptide Dramatically Lowers Plasma Cholesterol and Restores Endothelial Function in Watanabe Heritable Hyperlipidemic Rabbits

Himanshu Gupta, C. Roger White, Shaila Handattu, David W. Garber, Geeta Datta, Manjula Chaddha, Lijun Dai, Sandra H. Gianturco, William A. Bradley, and G.M. Anantharamaiah
Circulation 2005 111: 3112-3118. [Abstract] [Full Text]

Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage

Anette Fiebeler, Jürg Nussberger, Erdenechimeg Shagdarsuren, Song Rong, Georg Hilfenhaus, Nidal Al-Saadi, Ralf Dechend, Maren Wellner, Silke Meiners, Christiane Maser-Gluth, Arco Y. Jeng, Randy L. Webb, Friedrich C. Luft, and Dominik N. Muller
Circulation 2005 111: 3087-3094. [Abstract] [Full Text]